Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.

(NASDAQ:AZTA) Azenta, Inc. reported financial results for the fourth quarter and fiscal year ended September 30, 2026. For Q4 2026, revenue from continuing operations was $167 million, up 5% year over year, with organic growth of 2%. Sample Management Solutions revenue for the quarter was $94 million, up 9% year over year, while Multiomics revenue was $73 million, flat year over year. Diluted EPS from continuing operations for Q4 was $0.14, compared to $1.12 in Q4 2025, and total diluted EPS was $0.16, compared to $1.11 a year ago. Adjusted diluted EPS from continuing operations was $0.28, up from $0.21 in the prior year quarter. Adjusted EBITDA for Q4 was $19.4 million, with an adjusted EBITDA margin of 11.6%. For the full fiscal year 2026, revenue from continuing operations was $622 million, up 5% year over year, with organic growth of 2%. Sample Management Solutions revenue for the year was $344 million, up 6%, and Multiomics revenue was $277 million, up 3%. Diluted EPS from continuing operations for the year was ($3.50), compared to $0.53 in fiscal 2025, and total diluted EPS was ($3.70), compared to ($1.22) a year ago. Adjusted diluted EPS for the year was $0.48, compared to $0.51 in the prior year. Adjusted EBITDA for the year was $58.3 million, with an adjusted EBITDA margin of 9.4%. The company ended fiscal 2026 with $506 million in cash, cash equivalents, restricted cash, and marketable securities. Operating cash flow for the year was $58 million, capital expenditures were $30 million, and free cash flow was $27 million. On July 1, 2026, Azenta completed the sale of B Medical Systems and received full repayment of the $35 million vendor loan, with accrued interest, on September 3, 2026. On October 28, 2026, Azenta entered into agreements with Elegen Corp., obtaining an exclusive, royalty-free license to certain gene synthesis and cell-free cloning technologies for an initial five-year term, requiring fixed license payments totaling $23.0 million, with an option to convert to a perpetual license for $25.0 million plus unpaid fees. Aggregate capital deployment under the Elegen agreements is expected to range from $32.0 million to $71.0 million. Also on October 28, 2026, Azenta acquired SynPlexity Inc. for a base purchase price of $15.0 million in cash, with $2.5 million held back, and up to $10.0 million in contingent consideration based on revenue milestones through September 30, 2029. During fiscal 2026, Azenta repurchased 4.4 million shares of common stock for $118.2 million under its 2025 Repurchase Program, with $131.8 million remaining authorized for future repurchases as of September 30, 2026. For fiscal 2027, Azenta expects reported revenue from continuing operations to range from $648 to $660 million, with organic revenue growth of 3% to 5% year over year. Adjusted EBITDA margin is expected to expand by 200 to 250 basis points year over year, inclusive of a 100 basis point dilution from the Elegen and SynPlexity transactions. Free cash flow is expected to improve by approximately 25% relative to fiscal 2026. The company expects fiscal 2027 to focus on integration, scale-up, and commercialization of new capabilities from recent investments.

Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities

(NASDAQ:AZTA) Azenta, Inc. announced strategic investments to advance the next phase of growth for its GENEWIZ business. Azenta has entered into an exclusive licensing agreement with Elegen Corp., a developer of advanced cell-free DNA manufacturing technology. The license agreement brings an innovative cell-free DNA synthesis platform into the GENEWIZ portfolio, designed to improve DNA quality, delivery speed, and manufacturing scalability. The platform's capabilities include sequence-verified DNA constructs and templates to simplify preparation for downstream experiments, such as antibody discovery. The compact production workflows enable regional capacity to be added close to customers to respond to demand as needed. Azenta has also acquired SynPlexity Inc., a synthetic biology company providing high-throughput gene libraries for biological discovery. The acquisition adds pooled gene assembly technology that provides thousands of full-length gene variants in a single library. These capabilities address the increasing scale of biological design by enabling researchers to efficiently build and test large numbers of candidates, including AI-generated designs. Trey Martin, President, Multiomics at Azenta, stated that these strategic investments strengthen the competitive position of GENEWIZ by expanding the products and capabilities offered to customers and are key to accelerating growth. By combining these advanced technologies with Azenta's global infrastructure and existing gene-to-antibody portfolio, the company is building a differentiated platform to accelerate the next era of biologics discovery and development. Since its founding in New Jersey in 1999, GENEWIZ has built a global sequencing and gene synthesis business grounded in scientific expertise, customer focus, and operational excellence. These investments complement and extend that foundation into higher-growth applications across synthetic biology, protein engineering, and AI-enabled drug discovery. Additional details will be provided during Azenta's fourth quarter fiscal 2026 earnings call.

Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.

(NASDAQ:AZTA) Azenta, Inc. reported financial results for the third quarter ended June 30, 2026, with revenue from continuing operations of $161 million, up 12% year over year. Organic revenue increased 9% year over year, excluding a 1-percentage point impact from foreign exchange and a 3-percentage point impact from the acquisition of UK Biocentre Limited. Sample Management Solutions revenue was $88 million, up 14% year over year, and Multiomics revenue was $73 million, up 10% year over year. Adjusted EBITDA for continuing operations was $18.5 million, with an adjusted EBITDA margin of 11.4%. The company ended the quarter with $529 million in cash, cash equivalents, restricted cash, and marketable securities, and repurchased 2.3 million shares of common stock for $50.0 million under its 2025 Repurchase Program. The company projects total reported revenue from continuing operations for fiscal 2026 to range between $613 to $618 million, adjusted EBITDA to be in the range of $59 million to $62 million, and free cash flow to improve approximately 10% to 15% year-over-year. The company also expects total organic revenue for fiscal 2026 to range between flat to up 1% compared to fiscal 2025.

Azenta Completes Sale of B Medical Systems

(NASDAQ:AZTA) Azenta, Inc. announced the completion of the previously disclosed sale of its B Medical Systems business to Thelema S.à r.l. for a fixed purchase price of $63 million in cash. The transaction was originally announced on December 29, 2025 and closed on July 1, 2026 following the satisfaction of all closing conditions. Of the $63 million, $35 million was funded through a short-term secured vendor loan from an Azenta subsidiary to Thelema. Additional details regarding the transaction are available in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission. Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. The company projects enhanced financial flexibility and a continued focus on its core growth platforms, aiming to drive sustainable growth and long-term value for shareholders.

Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report

Azenta, Inc. (NASDAQ:AZTA) announced the publication of its annual Environmental, Social, & Governance (ESG) report for the fiscal year ended September 30, 2025. The report highlights the company's progress in ESG initiatives, including the first disclosure of Scope 3 GHG emissions and the establishment of a value chain emissions baseline. Azenta submitted near-term GHG reduction targets to the Science Based Targets initiative (SBTi), aiming for a 45% absolute reduction in Scope 1 and 2 emissions and a 25% reduction in Scope 3 emissions by FY2033 from a FY2025 base year. The company reduced its Scope 1 and 2 carbon footprint by approximately 40% compared to FY2022 and sourced 72% of its electricity from renewable sources. Other achievements include advancing sustainable innovation with the BioArc™ Ultra, completing its second annual Global Well-being Week, and expanding the Azenta Business System (ABS) across global operations. These efforts demonstrate Azenta's commitment to ESG priorities and operational improvements. The company encourages stakeholders to review the full ESG report for more details.